back to US directory
us clinical guidance

Pertussis recognition, treatment and public-health response

CDC-aligned clinical recognition, nasopharyngeal testing, early treatment, post-exposure prophylaxis and infant-risk escalation.

JurisdictionUnited States
Source check2026-08-20
Clinical reviewiatroX editorial team 路 Clinical editorial review 路 reviewed 2026-08-20 路 due 2027-08-20
AudienceUnited States healthcare professionals
This is an iatroX educational summary of named United States sources, not an official guideline. It does not replace the complete source documents, local policy, specialist advice or clinical judgement. Use the named authority, current FDA labeling, applicable state law, payer rules and local protocol where relevant.

Scope of this summary

Infants, children and adults with possible Bordetella pertussis infection or a significant exposure. Clinical features vary with age, vaccination and illness stage. This page is not a dosing table, immunization schedule or intensive-care protocol; antibiotic selection and prophylaxis require current CDC age-, pregnancy- and interaction-specific references.
sources for this section:CDC pertussis 2025

The Bottom Line

  • Suspect pertussis with paroxysmal cough, inspiratory whoop, post-tussive vomiting, apnea or a prolonged cough exposure, while recognizing that vaccinated adolescents and adults may lack a classic whoop.
  • Collect a nasopharyngeal swab or aspirate using the correct method and test according to illness timing; throat and anterior-nasal specimens are inadequate for standard pertussis diagnostics.
  • Treat early, ideally in the first one to two weeks, and consider treatment before results when clinical suspicion is strong or the patient or close contacts are at high risk.
  • Use a CDC-recommended macrolide or age-appropriate alternative after reviewing contraindications and resistance context, and prioritize post-exposure prophylaxis for household and high-risk contacts.
sources for this section:CDC pertussis 2025

Practical clinical workflow

1
Record cough onset, paroxysms, apnea, cyanosis, vomiting, fever, vaccination, pregnancy, infant or high-risk contacts, travel and prior antibiotic exposure; assess feeding, hydration and respiratory stability.
2
Notify the laboratory of the suspected diagnosis, collect the correct nasopharyngeal specimen before treatment when this will not cause delay, and interpret PCR or culture in relation to timing.
3
Start indicated treatment, provide droplet and exclusion advice under current public-health guidance, identify close contacts and coordinate prophylaxis or vaccination review with the health department.
4
Monitor infants and high-risk patients closely because cough severity can escalate after a mild catarrhal stage; review persistent symptoms for complications even after transmission risk has fallen.
sources for this section:CDC pertussis 2025

Safety boundaries and escalation

  • Apnea, cyanosis, bradycardia, hypoxemia, dehydration, feeding failure, seizure or exhaustion requires urgent hospital assessment; young infants can deteriorate without a prominent cough.
  • Azithromycin remains recommended in very young infants despite an association with infantile hypertrophic pyloric stenosis; explain the risk and monitor while prioritizing pertussis treatment.
  • Review QT prolongation, interacting medicines, severe liver disease and allergy before macrolide therapy, and use local resistance and travel history when treatment fails.
  • Pertussis is nationally notifiable and state rules govern reporting, isolation, school or work exclusion and contact management; a prescription alone does not complete care.
sources for this section:CDC pertussis 2025

Localization

CDC鈥檚 December 2025 treatment guidance and state or local health-department instructions govern US care. UKHSA exclusion, prophylaxis and notification rules are not portable. Vaccination status reduces severity but does not exclude infection, and ACIP catch-up decisions belong in the dedicated US immunization page.
sources for this section:CDC pertussis 2025

Source documents

Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.

  1. Centers for Disease Control and PreventionTreatment of Pertussisupdated 2025-12-02 路 accessed 2026-08-20
    view source
continue the learning

From guidance to deliberate practice and evidence

Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.

Add this guidance review to CPD/CMEOpen an editable learning-log record with this page鈥檚 provenance attached. You confirm the activity, time, reflection and mappings.Reflect on this with TutorUse optional prompts to consider what you learned and what鈥攊f anything鈥攜ou may change. Suggestions are never inserted automatically.Browse the US question bankKeep this guidance topic in view, then choose your exam and filters. No session starts automatically.
Found a source update or regional discrepancy? Tell the iatroX editorial team.